Jae-Hui Kim1, Ji Yun Jeong1, An Na Seo1, Nora Jee-Young Park1, Moonsik Kim2, Ji Young Park3. 1. Department of Pathology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. 2. Department of Pathology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea teiroa83@knuh.kr. 3. Department of Pathology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea jyparkmd@knu.ac.kr.
Abstract
BACKGROUND/AIM: Poorly differentiated thyroid carcinoma (PDTC), anaplastic thyroid carcinoma (ATC), and advanced DTC have poor outcomes. MATERIALS AND METHODS: We performed next-generation sequencing in nine selected aggressive thyroid cancers. RESULTS: Among the nine patients, the driver gene mutations BRAF V600E (3/9) and NRAS Q61K (1/9) were detected. Other oncogenic mutations included ERBB2 (1/9) and CDK4 (1/9). Telomerase reverse transcriptase (TERT) promoter mutation was found in five cases. Among tumor suppressor genes, mutations in TP53 (3/9), ARID1A (1/9), APC (1/9), MEN1 (1/9), DICER1 (1/9), and MED12 (1/9) were identified. RET fusions were found in two cases, one with PTDC and the other with ATC. The ATC with RET fusion also harbored TP53 and TERT promoter mutations. None of the PDTC cases had BRAF or RAS gene alterations. CONCLUSION: Since genetic alterations with therapeutic and prognostic implications were detected using next-generation sequencing, this technique is recommended to be performed for patients with aggressive thyroid cancer.
BACKGROUND/AIM: Poorly differentiated thyroid carcinoma (PDTC), anaplastic thyroid carcinoma (ATC), and advanced DTC have poor outcomes. MATERIALS AND METHODS: We performed next-generation sequencing in nine selected aggressive thyroid cancers. RESULTS: Among the nine patients, the driver gene mutations BRAF V600E (3/9) and NRAS Q61K (1/9) were detected. Other oncogenic mutations included ERBB2 (1/9) and CDK4 (1/9). Telomerase reverse transcriptase (TERT) promoter mutation was found in five cases. Among tumor suppressor genes, mutations in TP53 (3/9), ARID1A (1/9), APC (1/9), MEN1 (1/9), DICER1 (1/9), and MED12 (1/9) were identified. RET fusions were found in two cases, one with PTDC and the other with ATC. The ATC with RET fusion also harbored TP53 and TERT promoter mutations. None of the PDTC cases had BRAF or RAS gene alterations. CONCLUSION: Since genetic alterations with therapeutic and prognostic implications were detected using next-generation sequencing, this technique is recommended to be performed for patients with aggressive thyroid cancer.
Authors: Kris Ann P Schultz; Surya P Rednam; Junne Kamihara; Leslie Doros; Maria Isabel Achatz; Jonathan D Wasserman; Lisa R Diller; Laurence Brugières; Harriet Druker; Katherine A Schneider; Rose B McGee; William D Foulkes Journal: Clin Cancer Res Date: 2017-06-15 Impact factor: 12.531
Authors: Sofia Asioli; Lori A Erickson; Alberto Righi; Long Jin; Marco Volante; Sarah Jenkins; Mauro Papotti; Gianni Bussolati; Ricardo V Lloyd Journal: Mod Pathol Date: 2010-06-18 Impact factor: 7.842
Authors: Sam M Wiseman; Thom R Loree; Nestor R Rigual; Wesley L Hicks; Wade G Douglas; Garth R Anderson; Daniel L Stoler Journal: Head Neck Date: 2003-08 Impact factor: 3.147
Authors: Q Wei; Z Ye; X Zhong; L Li; C Wang; R E Myers; J P Palazzo; D Fortuna; A Yan; S A Waldman; X Chen; J A Posey; A Basu-Mallick; B H Jiang; L Hou; J Shu; Y Sun; J Xing; B Li; H Yang Journal: Ann Oncol Date: 2017-09-01 Impact factor: 32.976